Pharmaceutical Technology on MSN
Health Canada conditionally approves Gilead Sciences’ Lyvdelzi for PBC
Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi (seladelpar) for adults with primary biliary ...
Iqirvo (elafibranor) is a medicine that can help treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.
In medicine, treatment goals set by physicians might differ from patient priorities. Although normalisation of laboratory parameters is a target supported by outcomes data, patient perspectives ...
"PBC is one of those liver diseases where you can have cirrhosis and liver failure if you don't do anything about it in a matter of 10 to 15 years," said Lucy Mathew, NP, of Cedars Sinai in Los ...
Please provide your email address to receive an email when new articles are posted on . Eight years ago, Ocaliva was a prospective lifesaver for patients with primary biliary cholangitis who failed to ...
A primary biliary cholangitis (PBC) diagnosis can be life-changing. For many, it’s an emotional journey filled with questions, uncertainties and a need to redefine what life looks like with a chronic ...
BOSTON -- The investigational agent seladelpar improved markers of disease activity and pruritus in patients with primary biliary cholangitis (PBC) at risk of disease progression, a phase III trial ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.
In 2017, Maria Morais started to experience severe abdominal pain before eventually undergoing gall bladder surgery. When the procedure didn’t bring her the relief she hoped for, follow-up tests ...
Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid. People ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results